Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Everolimus 10 mg and pancreatic neuroendocrine tumours: many adverse effects and uncertain benefit.

[No authors listed]

Prescrire Int. 2012 Oct;21(131):234. Review.

PMID:
23185844
2.

Role of everolimus in pancreatic neuroendocrine tumors.

Goldstein R, Meyer T.

Expert Rev Anticancer Ther. 2011 Nov;11(11):1653-65. doi: 10.1586/era.11.145. Review.

PMID:
21932937
3.

Everolimus for advanced pancreatic neuroendocrine tumors.

Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group..

N Engl J Med. 2011 Feb 10;364(6):514-23. doi: 10.1056/NEJMoa1009290.

4.

Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.

Thompson LA, Kim M, Wenger SD, O'Bryant CL.

Ann Pharmacother. 2012 Sep;46(9):1212-9. doi: 10.1345/aph.1R087. Review.

PMID:
22947595
5.

A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.

Fazio N, Buzzoni R, Baudin E, Antonuzzo L, Hubner RA, Lahner H, DE Herder WW, Raderer M, Teulé A, Capdevila J, Libutti SK, Kulke MH, Shah M, Dey D, Turri S, Aimone P, Massacesi C, Verslype C.

Anticancer Res. 2016 Feb;36(2):713-9.

6.

Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.

Chan HY, Grossman AB, Bukowski RM.

Adv Ther. 2010 Aug;27(8):495-511. doi: 10.1007/s12325-010-0045-2. Review.

PMID:
20623346
7.

Everolimus in renal cell carcinoma.

Wang Y.

Drugs Today (Barc). 2010 Aug;46(8):557-66. doi: 10.1358/dot.2010.46.8.1516824. Review.

PMID:
20830316
8.

Pneumocystis jirovecii pneumonia under everolimus in two patients with metastatic pancreatic neuroendocrine tumors.

Carbonnaux M, Molin Y, Souquet PJ, Tantin A, Lombard-Bohas C, Walter T.

Invest New Drugs. 2014 Dec;32(6):1308-10. doi: 10.1007/s10637-014-0150-1.

PMID:
25119297
9.

Promising advances in the treatment of malignant pancreatic endocrine tumors.

Jensen RT, Delle Fave G.

N Engl J Med. 2011 Feb 10;364(6):564-5. doi: 10.1056/NEJMe1013903. No abstract available.

PMID:
21306243
10.

Recent studies show promise for treating rare pancreatic tumors.

Peres J.

J Natl Cancer Inst. 2011 Apr 20;103(8):624-7. doi: 10.1093/jnci/djr140. No abstract available.

11.

Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial.

Ito T, Okusaka T, Ikeda M, Igarashi H, Morizane C, Nakachi K, Tajima T, Kasuga A, Fujita Y, Furuse J.

Jpn J Clin Oncol. 2012 Oct;42(10):903-11.

12.
13.

Small tumors, intermediate models, big hopes.

Siu LL.

J Clin Oncol. 2010 Oct 10;28(29):4407-9. doi: 10.1200/JCO.2010.31.0094. No abstract available.

PMID:
20823413
14.

Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues.

Ferté C, Paci A, Zizi M, Gonzales DB, Goubar A, Gomez-Roca C, Massard C, Sahmoud T, André F, Soria JC.

Eur J Cancer. 2011 Oct;47(15):2249-55. doi: 10.1016/j.ejca.2011.03.017.

PMID:
21489779
15.

Everolimus for the treatment of pancreatic neuroendocrine tumors.

Feldmann G, Bisht S, Schütte U, Haarmann J, Brossart P.

Expert Opin Pharmacother. 2012 Oct;13(14):2073-84. doi: 10.1517/14656566.2012.713348. Review.

PMID:
22873789
16.

Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas.

Bollard J, Couderc C, Blanc M, Poncet G, Lepinasse F, Hervieu V, Gouysse G, Ferraro-Peyret C, Benslama N, Walter T, Scoazec JY, Roche C.

Neuroendocrinology. 2013;97(4):331-40. doi: 10.1159/000347063.

17.

Medical treatment of neuroendocrine tumours.

Weber HC.

Curr Opin Endocrinol Diabetes Obes. 2013 Feb;20(1):27-31. doi: 10.1097/MED.0b013e32835c034f. Review.

PMID:
23221494
18.

[Management of metabolic disorders induced by everolimus in patients with differentiated neuroendocrine tumors: expert proposals].

Lombard-Bohas C, Cariou B, Vergès B, Coriat R, N'guyen T, François E, Hammel P, Niccoli P, Hentic O.

Bull Cancer. 2014 Feb;101(2):175-83. doi: 10.1684/bdc.2014.1887. Review. French.

PMID:
24557872
19.

Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.

Raj N, Reidy-Lagunes D.

Hematol Oncol Clin North Am. 2016 Feb;30(1):119-33. doi: 10.1016/j.hoc.2015.09.005. Review.

PMID:
26614372
20.

Translational medicine: Cancer lessons from mice to humans.

Tuveson D, Hanahan D.

Nature. 2011 Mar 17;471(7338):316-7. doi: 10.1038/471316a. No abstract available.

PMID:
21412332
Items per page

Supplemental Content

Support Center